iStopMM Trial - Covid Vaccine and Impact on Myeloma | Malin Hultcrantz, MD, PhD | ASH 2022

Does SARS-CoV-2 vaccination impact the risk of progression from MGUS to Multiple Myeloma?Подробнее

Immune reconstitution and vaccination in multiple myelomaПодробнее

Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023Подробнее

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from iStopMMПодробнее

Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myelomaПодробнее

Correlation between SARS-CoV-2 RNA Vaccination in Myeloma Pts & Anti-CD38 & BCMA-Targeted TreatmentПодробнее

How has COVID-19 affected the myeloma field?Подробнее

Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022Подробнее

Hypercalcemia in Individuals with MGUS: Results from the iStopMM StudyПодробнее

Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma CohortПодробнее

The impact of the COVID-19 pandemic on myeloma treatmentПодробнее

Expert Perspective: COVID Vaccines and Treatment for Myeloma PatientsПодробнее

Impact of the COVID-19 pandemic on multiple myeloma treatmentПодробнее

Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMMПодробнее

iStopMM - One Year UpdateПодробнее

Should myeloma patients get a COVID-19 booster shot?Подробнее

An update on Myeloma, COVID-19, Vaccines and Cancer - 5 May 2022Подробнее

What is the current COVID-19 status for myeloma patients?Подробнее

Vaccination, booster shots, and COVID-19 with multiple myelomaПодробнее